1-3 of 3
David M Rodman, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL

Christiane Querfeld, MD PhD, Theresa Pacheco, MD, Francine M. Foss, MD, Ahmad S. Halwani, MD, Pierluigi Porcu, MD, Anita G Seto, PhD, Judy Ruckman, PhD, Michele L Landry, Aimee L Jackson, PhD, Linda A Pestano, PhD, Brent A Dickinson, Mark Sanseverino, David M Rodman, MD, Gilad Gordon, MD MBA, William Marshall, PhD
Journal: Blood
Blood (2016) 128 (22): 1829.
https://doi.org/10.1182/blood.V128.22.1829.1829
Published: 2016
Journal Articles

Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia

Nina C. Zitzer, DVM, Parvathi Ranganathan, PhD, Brent A Dickinson, BA, Aimee L Jackson, PhD, David M Rodman, MD, Carlo M. Croce, MD, Guido Marcucci, MD, Ramiro Garzon, MD
Journal: Blood
Blood (2015) 126 (23): 3802.
https://doi.org/10.1182/blood.V126.23.3802.3802
Published: 2015
Journal Articles

Preclinical Results Supporting Therapeutic Development of Mrg-106, an Oligonucleotide Inhibitor of Mir-155, in CTCL

Anita G Seto, PhD, Xuan T Beatty, BS, Linda A Pestano, PhD, Brent A Dickinson, BA, Marshelle S Warren, MD, David M Rodman, MD, Aimee L Jackson, PhD
Journal: Blood
Blood (2015) 126 (23): 2758.
https://doi.org/10.1182/blood.V126.23.2758.2758
Published: 2015